Form 8-K - Current report:
SEC Accession No. 0001140361-24-007259
Filing Date
2024-02-13
Accepted
2024-02-13 07:05:49
Documents
15
Period of Report
2024-02-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20021494_8k.htm   iXBRL 8-K 34512
2 EXHIBIT 99.1 ef20021494_ex99-1.htm EX-99.1 372213
  Complete submission text file 0001140361-24-007259.txt   571049

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20240213.xsd EX-101.SCH 3863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20240213_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20240213_pre.xml EX-101.PRE 16551
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20021494_8k_htm.xml XML 4375
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 24622567
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)